NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Australia charting 10-year strategy for blood cancer research

Published 11/12/2023, 03:29 pm
Updated 11/12/2023, 04:30 pm
Australia charting 10-year strategy for blood cancer research
EUR/USD
-

The Australian Academy of Science and the Australian Academy of Health and Medical Sciences, in collaboration with the Leukaemia Foundation, are actively seeking contributions to shape a 10-year plan aimed at accelerating blood cancer research in Australia.

This initiative represents a concerted effort to drive significant advancements in the treatment and understanding of blood cancers.

The proposed roadmap is comprehensive, focusing on leveraging cutting-edge technologies such as genomic testing and immunotherapies.

These innovative approaches offer the promise of more targeted and effective treatments, with recent progress in therapies like CAR T-cell treatment showcasing their potential in treating certain types of lymphoma and leukaemia.

Challenges

A significant challenge outlined in the roadmap is the need for increased funding.

Despite a substantial investment of A$125 million between 2018 and 2020, blood cancer research remains comparatively underfunded. Addressing this funding gap is crucial for the roadmap's success.

The document also emphasises Australia's strong reputation in scientific and medical research, advocating for high standards and robust guidelines.

This strong foundation is essential for the global recognition of Australian clinical trials and research findings.

Another focus area is the need to overcome geographical disparities in healthcare delivery, particularly in remote and rural communities.

Enhancing access to care in these areas is vital for positioning Australia as a leader in remote healthcare delivery.

The roadmap concludes with several critical questions aimed at refining research priorities and strategies, including aligning funding, addressing remote community challenges, and enhancing international research collaborations.

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.